_____

Notice of Maiden Q1 Results 2021

Siena, Italy, May 6th, 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, will announce its maiden First Quarter 2021 Results on **Wednesday 12th May 2021**.

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at **10:00am EST / 14:00pm BST / 15:00pm CEST** on Thursday **13th May 2021**.

For more details or to attend the virtual briefing, please contact philogen@consilium-comms.com.

About Philogen

Philogen is a Swiss-Italian, fully integrated, biotech company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and small organic ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical candidates in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is listed on the Italian stock exchange and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com and www.philochem.com.

For more information please contact:

Philogen

Dr. Christian Lizak (Business Development) / Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

christian.lizak@philogen.com / emanuele.puca@philogen.com

Consilium Strategic Communications

Mary-Jane Elliott, Melissa Gardiner, Davide Salvi

Philogen@consilium-comms.com

_____